Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.

Brander D, Islam P, Barrientos JC.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:487-498. doi: 10.1200/EDBK_238735. Epub 2019 May 17.

PMID:
31099686
2.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Apr 17:JCO1801460. doi: 10.1200/JCO.18.01460. [Epub ahead of print]

PMID:
30995176
3.

Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Gupta R, Li W, Yan XJ, Barrientos J, Kolitz JE, Allen SL, Rai K, Chiorazzi N, Mongini PKA.

J Immunol. 2019 May 15;202(10):2924-2944. doi: 10.4049/jimmunol.1801142. Epub 2019 Apr 15.

PMID:
30988120
4.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
5.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

PMID:
30767298
6.

Chylothorax in Patients with Chronic Lymphocytic Leukemia: A Case Series.

Sammartino D, Khanijo S, Koenig S, Katsetos JF, Tufano A, Rai KR, Barrientos JC.

J Hematol (Brossard). 2018 Jan;7(1):14-18. doi: 10.14740/jh339w.

7.

Renal involvement in chronic lymphocytic leukemia.

Wanchoo R, Bernabe Ramirez C, Barrientos J, Jhaveri KD.

Clin Kidney J. 2018 Oct;11(5):670-680. doi: 10.1093/ckj/sfy026. Epub 2018 Apr 11.

8.

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.

Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ.

Leuk Lymphoma. 2019 Apr;60(4):1000-1005. doi: 10.1080/10428194.2018.1512710. Epub 2018 Oct 2.

9.

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.

10.

Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Gupta R, Yan XJ, Barrientos J, Kolitz JE, Allen SL, Rai K, Chiorazzi N, Mongini PKA.

J Immunol. 2018 Sep 1;201(5):1570-1585. doi: 10.4049/jimmunol.1800591. Epub 2018 Aug 1.

PMID:
30068596
11.

Can umbralisib bring PI3Kδ out of the shadows?

Barrientos JC.

Lancet Oncol. 2018 Apr;19(4):432-434. doi: 10.1016/S1470-2045(18)30154-2. Epub 2018 Feb 20. No abstract available.

PMID:
29475725
12.

Adverse events in critical care: Search and active detection through the Trigger Tool.

Molina FJ, Rivera PT, Cardona A, Restrepo DC, Monroy O, Rodas D, Barrientos JG.

World J Crit Care Med. 2018 Feb 4;7(1):9-15. doi: 10.5492/wjccm.v7.i1.9. eCollection 2018 Feb 4.

13.

[Health and wellbeing of sexual minorities].

Barrientos J, Gómez F, Cárdenas M, Gúzman M, Bahamondes J.

Rev Med Chil. 2017 Sep;145(9):1115-1121. doi: 10.4067/s0034-98872017000901115. Spanish.

14.

Direct and Indirect Effects of Perceived Stigma on Posttraumatic Growth in Gay Men and Lesbian Women in Chile.

Cárdenas M, Barrientos J, Meyer I, Gómez F, Guzmán M, Bahamondes J.

J Trauma Stress. 2018 Feb;31(1):5-13. doi: 10.1002/jts.22256. Epub 2018 Feb 7.

PMID:
29412480
15.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

16.

Relation between HIV status, risky sexual behavior, and mental health in an MSM sample from three Chilean cities.

Gómez F, Barrientos J, Cárdenas M.

Rev Panam Salud Publica. 2017 Apr 20;41:e4.

PMID:
28444004
17.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.

Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.

18.

Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR.

Blood. 2017 May 4;129(18):2581-2584. doi: 10.1182/blood-2016-10-742437. Epub 2017 Feb 21. No abstract available.

19.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R.

Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.

20.

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Montillo M, O'Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, Brown JR, Barrientos JC, Mulligan SP, Furman RR, Cymbalista F, Plascencia C, Chang S, Hsu E, James DF, Hillmen P.

Blood Cancer J. 2017 Feb 3;7(2):e524. doi: 10.1038/bcj.2017.5. No abstract available.

21.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P.

Lancet Oncol. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.

22.

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR.

Leukemia. 2017 Jun;31(6):1348-1354. doi: 10.1038/leu.2017.34. Epub 2017 Jan 24.

23.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

24.

Sequencing of chronic lymphocytic leukemia therapies.

Barrientos JC.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):128-136. Review.

25.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

26.

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP.

Blood Adv. 2016 Nov 30;1(2):122-131. doi: 10.1182/bloodadvances.2016000976. eCollection 2016 Dec 13.

27.

[Non traumatic posterior instability in primary total knee replacement and its revision].

Carbó E, Laguna R, Del Moral F, Barrientos J, Vaquero J.

Acta Ortop Mex. 2016 Mar-Apr;30(2):105-109. Spanish.

28.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

29.

Introduction: Sexual Minorities' Discrimination in Iberian and Latin American Countries.

Barrientos J, Nardi HC.

J Homosex. 2016 Nov;63(11):1443-1445. doi: 10.1080/00918369.2016.1222823. No abstract available.

PMID:
27715770
30.

Subjective Wellbeing and Levels of Clinical Symptomatology in a Transwomen Sample and Men Who Have Sex With Men in Chile.

Barrientos J, Gómez F, Cárdenas M.

J Homosex. 2016 Nov;63(11):1502-1516. doi: 10.1080/00918369.2016.1223346.

PMID:
27715498
31.

Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support.

Seiter K, Stiefel MF, Barrientos J, Shaikh A, Ahmed N, Baskind P, Liu D.

Stem Cell Investig. 2016 Jul 4;3:27. doi: 10.21037/sci.2016.06.08. eCollection 2016.

32.

Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Barrientos JC.

Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21. Review.

PMID:
27324214
33.

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.

Barrientos JC.

Onco Targets Ther. 2016 May 18;9:2945-53. doi: 10.2147/OTT.S102573. eCollection 2016. Review.

34.

Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Patten PE, Ferrer G, Chen SS, Simone R, Marsilio S, Yan XJ, Gitto Z, Yuan C, Kolitz JE, Barrientos J, Allen SL, Rai KR, MacCarthy T, Chu CC, Chiorazzi N.

JCI Insight. 2016 Apr 7;1(4). pii: e86288.

35.

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS.

Am J Hematol. 2016 Mar;91(3):308-12. doi: 10.1002/ajh.24265. Epub 2016 Feb 9.

36.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

37.

Management of Chronic Lymphocytic Leukemia in the Elderly.

Barrientos JC.

Cancer Control. 2015 Oct;22(4 Suppl):17-23. Review.

38.

Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.

Sherry B, Jain P, Chiu PY, Leung L, Allen SL, Kolitz JE, Rai KR, Barrientos J, Liang S, Hawtin R, Chiorazzi N.

Immunol Res. 2015 Dec;63(1-3):216-27. doi: 10.1007/s12026-015-8722-5.

39.

Differential ant exclusion from canopies shows contrasting top-down effects on community structure.

Mestre L, Piñol J, Barrientos JA, Espadaler X.

Oecologia. 2016 Jan;180(1):193-203. doi: 10.1007/s00442-015-3442-z. Epub 2015 Sep 16.

PMID:
26376660
40.

Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.

Cui X, Zhang L, Magli AR, Catera R, Yan XJ, Griffin DO, Rothstein TL, Barrientos J, Kolitz JE, Allen SL, Rai KR, Chiorazzi N, Chu CC.

Leukemia. 2016 Jan;30(1):74-85. doi: 10.1038/leu.2015.204. Epub 2015 Jul 29.

41.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM.

Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.

PMID:
26193343
42.

TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, Bandovic J, Stankovic T, Barrientos J, Kolitz JE, Allen SL, Rai K, Chu CC, Chiorazzi N.

J Immunol. 2015 Aug 1;195(3):901-23. doi: 10.4049/jimmunol.1403189. Epub 2015 Jul 1.

43.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S.

Blood. 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9.

44.

Efficient reduction of pathogenic and spoilage microorganisms from apple cider by combining microfiltration with UV treatment.

Zhao D, Barrientos JU, Wang Q, Markland SM, Churey JJ, Padilla-Zakour OI, Worobo RW, Kniel KE, Moraru CI.

J Food Prot. 2015 Apr;78(4):716-22. doi: 10.4315/0362-028X.JFP-14-452.

PMID:
25836396
45.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S.

Blood. 2015 May 7;125(19):2915-22. doi: 10.1182/blood-2014-09-585869. Epub 2015 Mar 9.

46.

Management of adverse events associated with idelalisib treatment: expert panel opinion.

Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD.

Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19. Review.

47.

Nine new species of Phoridae (Insecta: Diptera) from Spain.

García-Romera C, Barrientos JA.

Zootaxa. 2014 Aug 28;3857(2):244-60. doi: 10.11646/zootaxa.3857.2.5.

PMID:
25283107
48.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

49.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

50.

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.

Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC.

Blood. 2014 Jul 3;124(1):42-8. doi: 10.1182/blood-2014-02-555722. Epub 2014 May 27. Erratum in: Blood. 2014 Sep 11;124(11):1848.

Supplemental Content

Loading ...
Support Center